mAb anti-Amyloid β Peptide N-terminal, NT 6C8

Description: Mouse monoclonal antibody against N-terminal sequence of human amyloid beta peptides

Purification: Protein G affinity purified

Target Protein: N-terminal sequence of human beta amyloid peptide

Immunogen: N-terminal peptide (DAEFRHDS) of human beta amyloid peptides, conjugated with KLH

Fusion Myeloma: Sp2/0-Ag14

Specificity: This antibody recognizes the N-terminal peptide (DAEFRHDS) of human beta amyloid peptides and also reacts with full length Aβ40, Aβ42 and Aβ43. 

Species Reacitvity: Human

Host / Isotype: Mouse, IgG1 Kappa

Formulation: Lyophilized from a solution in 0.01M PBS pH7.2

Reconstitution: Double distilled water is recommended to adjust the final concentration to 1.00mg/mL. 

Storage: Store at -20^oC

Research Area: Aging and neurodegenerative diseases

Background:  

Amyloid beta peptides Aβ42 and Aβ40 have been investigated extensively for predicating Alzheimer’s disease.  A recent study on amyloid beta peptide Aβ43 in brain showed that Aβ43 is more fibrillogenic than other amyloid beta peptides and could be more useful as a biomarker or therapeutic target for Alzheimer’s disease. 

Since Aβ40, Aβ42 and Aβ43 are different only at the few C-end amino acids, antibody to N-terminal sequence can bind with all three amyloid beta peptides.

Application: Immunohistochemistry, ELISA

References:

Y Zhang et al., Amyloid-β induces hepatic insulin resistance in vivo via JAK2. Diabetes (2013) 62, 4:1159-1166

If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.